Extensive Analysis on Generation and Consensus Mechanisms of Clustering Ensemble: A Survey

Data analysis plays a prominent role in interpreting various phenomena. Data mining is the process to hypothesize useful knowledge from the extensive data. Based upon the classical statistical prototypes the data can be exploited beyond the storage and management of the data. Cluster analysis a primary investigation with little or no prior knowledge, consists of research and development across a wide variety of communities. Cluster ensembles are melange of individual solutions obtained from different clusterings to produce final quality clustering which is required in wider applications. The method arises in the perspective of increasing robustness, scalability and accuracy. This paper gives a brief overview of the generation methods and consensus functions included in cluster ensemble. The survey is to analyze the various techniques and cluster ensemble methods

Optimal of 1-bit Comparator design and Energy Estimation using Quantum Dot Cellular Automata

Performance of CMOS technology has been affected in nanosystems due to power dissipation, area, and reliability functionalities. A research initiative which investigates other possible systems with related capacities is QCA. In this paper, QCA nanotechnology was used to create a 1-bit comparator. These circuits are easy to create and do not require any crossovers. The proposed design is extremely efficient in terms of area, cell count, quantum cost and delay, which improves the performance in the range of 74.81% to 99.87%  in terms of quantum cost. As a result, proposed designs are often found in various digital logics that require a small amount of space and low power consumption

DEVELOPMENT AND EVALUATION OF CLOBETASOL–LOADED SOLID LIPID NANOPARTICLES FOR TOPICAL TREATMENT OF PSORIASIS

Objective: The current research was structured to achieve a maximum topical delivery for the drug clobetasol-17-propionate (CP) and to predict the effects of various independent variables like lipid: drug ratio, surfactant, and homogenization time on particulate characters and performance solid lipid nanoparticles (SLNs). Methods: CP loaded SLNs were formulated by Emulsification–Homogenization method and optimized using 33 full factorial designs (Design-Expert software 11.0). Drug loaded SLNs were evaluated for various parameters like particle size, surface charge, polydispersity index, entrapment efficiency, surface morphology, thermal analysis, in vitro drug release through skin (Franz diffusion cell), drug deposition study and stability. Results: The optimized formulation (SLNs) attains a minimal Particle size of 133.3±3.66 nm, Poly dispersibility index of 0.179±0.081, % entrapment efficiency of 78.1±1.11 and Zeta potential of-36.2±0.11mV. Skin permeation study of CP loaded SLNs suspension showed prolonged drug release up to 24h. Maximum drug deposition was obtained after developing the drug into SLNs (48.22µg/ml) when compared to the pure drug (19.12µg/ml). Conclusion: SLNs were promising colloidal particulate carriers by which prolonged drug release and improved skin permeation was achieved for the drug Clobetasol 17- propionate

Assessment of insecticides and Cry2AB toxin resistance development in Karnataka population of Plutella xylostella (Linn.)

Insecticidal resistance studies against third instar larvae of DBM (Plutella xylostella L.) were carried out to know the rate of development of resistance from F1 to F3 generations in Karnataka population. The third instar larvae obtained from field were subjected to bioassay studies with tested against acephate, cypermethrin, spinosad, cartap hydrochloride and Cry2Ab toxin using leaf dip method to calculate LC50 values. The LC50 values of the insecticides were further used to quantify the resistance in P. xylostella of parental generation (F0) from Karnataka field population. The survivals from F0 generation were reared to next generation (F1). Resistance development studies was assessed from F1 to F3 generation with third instar larvae in every generation with a concentration that caused 80.00 % mortality for all the test insecticides and Cry2Ab toxin. Results revealed that ((0.17 folds) no resistance was developed against acephate in F3 generation. In case of cypermethrin 2.33 folds. Resistance studies further revealed that 1.50 folds resistance was developed against spinosad, 2.28 folds against cartap hydrochloride and Cry2Ab toxin 1.49 folds resistance was recorded in F3 generation. The rate of development of resistance from F1 to F3 generations increased in all the test insecticides and Cry toxin, except against acephate in Karnataka population. This data will be useful in the development of insecticide resistance management approach for DBM

An IoT Framework for Addressing Parents Concerns about Safety of School Going Children

In this paper, we have proposed a novel application using Internet of things (IOT). This application is focused to address the concerns of the parents towards their school going kids. Mainly the concerns of the parents are to ensure the safety of their kids in school bus as well as at school premises. In this paper, we have tried to provide detailed technical implementation about how different sensing, communication technologies clubbing together provides a platform in terms of IoT, where proposed application can be implemented to ensure safety of school going children as it is the priority and concern for parents. In Proposed application, parents get notification when his child boards the bus for school and gets down the bus at home’s doorstep. Parents also get notification when child enters his Class Room first time in a day. Parents any time can access the location his child or school bus in which his child is travelling. In case of emergency, child can disseminate the signal to parents / Single point of contact (SPOC) at school to make them aware about emergency

Genetic diversity assessment using RAPD primers in insecticide resistant populations of diamondback moth Plutella xylostella (Linn.)

Genetic diversity in acephate, spinosad and Cry2Ab resistant Plutella xylostella collected from three states of India was assessed by RAPD markers. The DNA extracted from larvae was subjected to polymerase chain reaction using 10 RAPD primers. The highest number alleles (7) were produced by primer ABA-13, followed by six alleles each by primers ABA-2, 7, 8, 11, 14; five alleles each were produced by ABA-4, 9, 10, 12. UPGMA analysis clustered the acephate, spinosad and Cry2Ab treated P.xylostella populations into two groups with overall similarity level of 33%, 27% and 34% respectively. Cluster A consisted 11 samples while Cluster B consisted only F1 of acephate and spinosad treated Karnataka population. In Cry2Ab treated population Cluster B comprised 11 samples and Cluster A had out grouped singly i.e. F0 generation from Karnataka. The genetic variability between the acephate, spinosad and Cry2Ab treated populations ranged from 33 to 69%, 27 to 56% and 34 to 69% respectively. Acephate and spinosad treated F1 population and Cry2Ab treated F0 population from Karnataka were out grouped from rest of the populations

Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) – A Strategic Option for India

The current HIV/AIDS scenario in India is quite grim with an estimated 2.4 million people living with HIV/AIDS (PLHA) in 2008, just behind South Africa and Nigeria. The anti-retroviral drugs (ARVs) remain the main stay of global HIV/AIDS treatment. Over 30 ARVs (single and FDCs) available under six categories viz., NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), Protease inhibitors, the new Fusion inhibitors, Entry inhibitors-CCR5 co-receptor antagonists and HIV integrase strand transfer inhibitors. The major originator companies for these ARVs are: Abbott, Boehringer Ingelheim (BI), Bristol-Myers Squibb (BMS), Gilead, GlaxoSmithKline (GSK), Merck, Pfizer, Roche, and Tibotec. Beginning with zidovidine in 1987, all the drugs are available in the developed countries. In India, about 30 ARVs are available as generics manufactured by Aurobindo, Hyderabad, Andhra Pradesh; Cipla Limited, Goa; Emcure Pharmaceuticals, Pune, Maharashtra; Hetero Drugs, Hyderabad, Andhra Pradesh; Macleods Pharmaceuticals, Daman; Matrix Laboratories, Nashik, Maharashtra; Ranbaxy, Sirmour, Himachal Pradesh; and Strides Arcolab, Bangalore, Karnataka. The National AIDS Control Organization (NACO) set up in 1992 by the Govt. of India provides free ARVs to HIV positive patients in India since 2004. The drugs available in India include both single drugs and FDCs covering both first line and second line ARVs. Even while there are claims of stabilization of the disease load, there is still huge gap of those who require ARVs as only about 150,000 PLHA receive the ARVs from the Govt. and other sources. Access to ARVs therefore is still a cause of serious concern ever since India became fully Trade Related Aspects of Intellectual Property Rights (TRIPS)-complaint in 2005. Therefore, the Indian pharmaceutical companies cannot make generics for those for drugs introduced post-2005 due to product patent regime. Other concerns include heat stable, other better formulations and second line ARVs for adults and more drugs and formulations for paediatric groups, that are still to be widely available in India and other developing countries. To examine whether strong intellectual property (IP) protection systems are to be considered important barriers for the limited or lack of access to ARVs, we studied the patent profile of the ARVs of the originator companies within and outside India. We could record 93 patents in the United States Patent & Trademark Office (USPTO). The originator companies have been also aggressively filing and enforcing patents in India. There have been a few efforts by companies like Gilead and GSK to grant licenses to generic manufacturers in developing countries, ostensibly to promote access to ARVs through lower (two-tier) pricing. These steps are considered as too little and too late. There is an urgent need to look for alternative strategies to promote access to ARVs both linked to and independent of IPRs. Patent pooling as a viable strategy mooted by the UNITAID should be seriously explored to promote access to ARVs. India is ideally suited for trying out the patent pool strategy as most of the global requirement of affordable ARV drugs for HIV/AIDS treatment is sourced from Indian generic companies